K. Mohler

发表

Interleukin 1-induced pathophysiology: induction of cytokines, development of histopathologic changes, and immunopharmacologic intervention.

R. L. Cain, L. Butler, A. Bendele, 1989, Clinical immunology and immunopathology.

Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery.

K. Mohler, M. Kennedy, D. Torrance, 1992, Journal of immunology.

Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome.

A. Cosimi, K. Mohler, S. Wee, 1996, Transplantation.

Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.

R. Black, J. Skotnicki, J. Levin, 2003, Bioorganic & medicinal chemistry letters.

Inflammation Roles for p 55 and p 75 in Several Models of TNF Receptor-Deficient Mice Reveal Divergent

C. Ware, P. Morrissey, J. Peschon, 1998 .

Chapter 24. Agents that Block TNF-α Synthesis or Activity

R. Black, K. Mohler, T. Bird, 1997 .

Identification and Characterization of 4-[[4-(2-Butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a Novel Dual Tumor Necrosis Factor-α-Converting Enzyme/Matrix Metalloprotease Inhibitor for the Treatment of Rheumatoid Arthritis

R. Black, M. Hegen, M. Feldmann, 2004, Journal of Pharmacology and Experimental Therapeutics.

Identification and Characterization of 4-[ [ 4-( 2-Butynyloxy ) phenyl ] sulfonyl ]-N-hydroxy-2 , 2-dimethyl-( 3 S )-thiomorpholinecarboxamide ( TMI-1 ) , a Novel Dual Tumor Necrosis Factor-- Converting Enzyme / Matrix Metalloprotease Inhibitor for the Treatment of Rheumatoid Arthritis

R. Black, M. Hegen, M. Feldmann, 2004 .

Relaxed specificity of matrix metalloproteinases (MMPS) and TIMP insensitivity of tumor necrosis factor-alpha (TNF-alpha) production suggest the major TNF-alpha converting enzyme is not an MMP.

Y. Okada, B. Castner, M. Gerhart, 1996, Biochemical and biophysical research communications.

Quantitation of cytokine mRNA levels utilizing the reverse transcriptase-polymerase chain reaction following primary antigen-specific sensitization in vivo--I. Verification of linearity, reproducibility and specificity.

L. Butler, K. Mohler, 1991, Molecular immunology.

Biological effects and fate of a soluble, dimeric, 80-kDa tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapy.

D. Schoenfeld, A. Cosimi, K. Mohler, 1997, Transplantation.

Role of the type 1 TNF receptor in lung inflammation after inhalation of endotoxin or Pseudomonas aeruginosa.

E. Chi, J. Peschon, T. Martin, 1999, The American journal of physiology.

Role of the type 1 TNF receptor in lung inflammation after inhalation of endotoxin or Pseudomonas aeruginosa.

E. Chi, J. Peschon, T. Martin, 1999, American journal of physiology. Lung cellular and molecular physiology.

The Locus of Tumor Necrosis Factor- α Action in Lung Inflammation

E. Chi, K. Mohler, Christopher B Wilson, 1998 .

Identification and Characterization of TMI-1, a Novel Dual TACE/MMP Inhibitor for the Treatment of RA

M. Hegen, M. Feldmann, P. Frost, 2003 .

Induction of B cell costimulatory function by recombinant murine CD40 ligand

C. Janeway, K. Mohler, K. Grabstein, 1994, European journal of immunology.

CD40/CD40 ligand interactions are required for T cell‐dependent production of interleukin‐12 by mouse macrophages

K. Mohler, W. Fanslow, W. Chin, 1996, European journal of immunology.

Interleukin-2 induced systemic toxicity: induction of mediators and immunopharmacologic intervention.

R. L. Cain, L. Butler, A. Bendele, 1989, Immunopharmacology and immunotoxicology.

Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection

S. Reed, P. Morrissey, K. Mohler, 1992, The Journal of experimental medicine.

Periosteal Hyperostosis (Exostosis) in DBA/1 Male Mice

K. Mohler, J. Schuh, R. Hall, 2002, Toxicologic pathology.

Identification of a distinct low-affinity receptor for human interleukin-4 on pre-B cells.

S. Ziegler, C. March, C. Rauch, 1993, Blood.

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

E. Tindall, L. Moreland, K. Mohler, 1997, The New England journal of medicine.

A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes

R. Black, C. Ware, K. Mohler, 1995, The Journal of experimental medicine.

The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.

F. C. Nelson, R. Black, J. Skotnicki, 2001, Bioorganic & medicinal chemistry letters.

Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys

Y. Vugmeyster, A. Wahl, K. Mohler, 2011, Rheumatology.

Cytokine and cytotoxic pathways of NK cell rejection of class I-deficient bone marrow grafts: influence of mouse colony environment.

L. Schook, M. Rutherford, K. Mohler, 1998, International immunology.

Further evidence for a common mechanism for shedding of cell surface proteins

B. Castner, R. Black, M. Wolfson, 1997, FEBS letters.

The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.

F. C. Nelson, R. Black, J. Skotnicki, 2001, Bioorganic & medicinal chemistry letters.

Differential production of IL-2 and IL-4 mRNA in vivo after primary sensitization.

L. Butler, K. Mohler, 1990, Journal of Immunology.

Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.

R. Black, J. Skotnicki, J. Levin, 2003, Bioorganic & medicinal chemistry letters.

Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.

C A Smith, C. Smith, V. Fung, 1993, Journal of immunology.

Fully human CD19-specific chimeric antigen receptors for T-cell therapy

S. Riddell, S. Shamah, K. Mohler, 2017, Leukemia.

TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation.

C. Ware, P. Morrissey, J. Peschon, 1998, Journal of immunology.

Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors.

M. Gerhart, C. Smith, D. Friend, 1997, Virology.

Pharmacokinetic parameters and biodistribution of soluble cytokine receptors.

C. Maliszewski, K. Mohler, W. Fanslow, 1993, International review of experimental pathology.

Tolerance to class II major histocompatibility complex molecules is maintained in the presence of endogenous, interleukin-2-producing, tolerogen-specific T lymphocytes.

K. Mohler, J. Streilein, 1987, Journal of immunology.

Susceptibility of Allo-Ia Specific T Lymphocytes to Unresponsiveness in Neonatal Tolerance

K. Mohler, R. Gruchalla, J. Streilein, 1983 .

Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing

M. Gerhart, R. Black, C. March, 1994, Nature.

In vitro detection of lymphokines produced by in vivo activated lymphocytes.

L. Butler, K. Mohler, 1989, Journal of immunological methods.

A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor.

R. Black, S. Rose-John, K. Mohler, 1995, Journal of immunology.

Immune function in patients with rheumatoid arthritis treated with etanercept.

Bucy Rp, M. Weinblatt, L. Moreland, 2002, Clinical immunology.

The locus of tumor necrosis factor-alpha action in lung inflammation.

E. Chi, K. Mohler, C. Wilson, 1998, American Journal of Respiratory Cell and Molecular Biology.

Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.

F. C. Nelson, R. Black, J. Skotnicki, 2002, Bioorganic & medicinal chemistry letters.

TRU-015, a novel CD20-directed biologic therapy, demonstrates significant anti-tumor activity in human tumor xenograft models

J. Ledbetter, K. Mohler, M. Hayden-Ledbetter, 2005 .

Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.

R. Black, J. Skotnicki, J. Levin, 2003, Bioorganic & medicinal chemistry letters.

of B cell

K. Mohler, K. Grabstein, M. Kennedy, 2022 .